Elutia Inc.
ELUT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708527
No open-market purchases or sales by Elutia Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Elutia Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 19 | 18 | −1 |
| Shares | 4.34M | 2.78M | −1.56M (−35.9%) |
| Value | $18.4M | $4.20M | −$14.2M (−77.2%) |
New holders (4)
Institutions that held Elutia Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Indie Asset Partners, LLC | 26,500 | $40.0K | 0.05% |
| Renaissance Technologies LLC | 21,916 | $33.0K | 0.00% |
| Jane Street Group, LLC | 19,042 | $28.8K | 0.00% |
| WealthPLAN Partners, LLC | 34 | $51 | 0.00% |
Sold out (5)
Institutions that held Elutia Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Endurant Capital Management LP | 1,259,544 | $5.35M |
| Platinum Investment Management Ltd | 188,181 | $799.8K |
| Pentwater Capital Management LP | 125,000 | $531.3K |
| Bridgeway Capital Management, LLC | 24,900 | $105.8K |
| Bank of America Corp | 24 | $102 |